Want to see IPSC full AI Analyst Report?
IPSC Stock Chart & Stats
$2.11
-$0.02(-0.95%)
At close: 4:00 PM EDT
$2.11
-$0.02(-0.95%)
Day’s Range― - ―
52-Week Range$0.44 - $3.04
Previous Close$2.08
Volume496.67K
Average Volume (3M)1.69M
Market Cap
$371.53M
Enterprise Value$423.11
Total Cash (Recent Filing)$119.71M
Total Debt (Recent Filing)$34.63M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Nov 05, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding180,354,810
10 Day Avg. Volume942,292
30 Day Avg. Volume1,686,024
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.54
Price to Sales (P/S)0.79
P/FCF Ratio-0.82
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.90Price Target Upside179.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.45
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Allogeneic IPSC PlatformCentury's iPSC allogeneic platform targets off-the-shelf NK and T cells, enabling scalable manufacturing and faster commercial throughput versus autologous approaches. This structural advantage can lower per-dose cost and support durable market penetration as cell therapies scale.
Pipeline Advancement — CNTY-813Robust preclinical results and an established Phase 1 manufacturing process materially de-risk CNTY-813's translational path. The planned IND (Q4 2026) and differentiated diabetes program diversify the pipeline, enhancing long-term commercial optionality beyond oncology and attracting partner interest.
Conservative LeverageLow debt relative to equity gives Century financial flexibility to fund continued R&D and clinical runs without large interest burdens. Modest leverage reduces default risk and preserves strategic optionality for partnerships or staged financing over multiple clinical milestones.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow indicates the company requires recurring external financing to support trials and manufacturing. Continued cash burn increases execution risk, can delay development timelines, and raises the probability of dilutive capital raises over the medium term.
Heavily Loss-making With Volatile RevenuePersistent net losses and deeply negative margins show the business is far from sustainable profitability. Volatile, inconsistent revenue undermines cash visibility and complicates reinvestment planning, making long-term execution and partner negotiations more challenging without further de-risking.
Shareholder Dilution RiskBoard-approved expansion of authorized shares and related financing flexibility materially increases the company's ability to issue equity. Given ongoing cash needs, this raises the realistic risk of future dilution, which can erode existing equity value and affect long-term investor returns.
Century Therapeutics News
IPSC FAQ
What was Century Therapeutics, Inc.’s price range in the past 12 months?
Century Therapeutics, Inc. lowest stock price was $0.43 and its highest was $3.04 in the past 12 months.
What is Century Therapeutics, Inc.’s market cap?
Century Therapeutics, Inc.’s market cap is $371.53M.
When is Century Therapeutics, Inc.’s upcoming earnings report date?
Century Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 83 days.
How were Century Therapeutics, Inc.’s earnings last quarter?
Century Therapeutics, Inc. released its earnings results on Aug 12, 2026. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.11 by -$0.06.
Is Century Therapeutics, Inc. overvalued?
According to Wall Street analysts Century Therapeutics, Inc.’s price is currently Undervalued.
Does Century Therapeutics, Inc. pay dividends?
Century Therapeutics, Inc. does not currently pay dividends.
What is Century Therapeutics, Inc.’s EPS estimate?
Century Therapeutics, Inc.’s EPS estimate is -0.11.
How many shares outstanding does Century Therapeutics, Inc. have?
Century Therapeutics, Inc. has 180,354,810 shares outstanding.
What happened to Century Therapeutics, Inc.’s price movement after its last earnings report?
Century Therapeutics, Inc. reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.11. Following the earnings report the stock price went down -4.854%.
Which hedge fund is a major shareholder of Century Therapeutics, Inc.?
Currently, no hedge funds are holding shares in IPSC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Century Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.90 (179.62% Upside)
$5.90 (179.62% Upside)
Blogger Sentiment
Bullish
IPSC Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 33.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $11.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.8%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
220.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.47%
Trailing 12-Months
Company Description
Century Therapeutics, Inc.
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
IPSC Stock 12 Month Forecast
Average Price Target
$5.90
▲(179.62% Upside)
Technical Analysis
Tempest Therapeutics
―
Actinium Pharmaceuticals
―
Bioxcel Therapeutics
―
Lantern Pharma
―
CalciMedica
―
Ownership Overview
3.31% Insiders
3.55% Mutual Funds
6.86% Other Institutional Investors
79.37% Public Companies and
Individual Investors